Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Target Price at $61.08

Janux Therapeutics, Inc. (NASDAQ:JANX) has received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $61.0833.

A number of research analysts have recently issued reports on JANX shares. HC Wainwright dropped their price target on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Cantor Fitzgerald lowered their target price on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, December 2nd. Wolfe Research began coverage on shares of Janux Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. UBS Group reaffirmed a “buy” rating and set a $57.00 price target on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $45.00 price target (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 1,879 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $25,798.67. Following the transaction, the insider directly owned 83,095 shares in the company, valued at approximately $1,140,894.35. This represents a 2.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Charles M. Winter sold 2,401 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $32,965.73. Following the sale, the insider directly owned 77,721 shares of the company’s stock, valued at approximately $1,067,109.33. This trade represents a 3.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 42,364 shares of company stock valued at $972,185 over the last ninety days. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of JANX. Vanguard Group Inc. grew its holdings in Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after purchasing an additional 227,676 shares during the period. Orbimed Advisors LLC raised its holdings in shares of Janux Therapeutics by 45.9% during the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock valued at $43,163,000 after purchasing an additional 555,800 shares during the period. Readystate Asset Management LP boosted its position in shares of Janux Therapeutics by 38.0% during the 3rd quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock worth $23,472,000 after purchasing an additional 264,423 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Janux Therapeutics by 15.5% during the 2nd quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock worth $20,845,000 after purchasing an additional 121,403 shares in the last quarter. Finally, Prosight Management LP grew its stake in shares of Janux Therapeutics by 1.3% in the 3rd quarter. Prosight Management LP now owns 865,350 shares of the company’s stock valued at $21,149,000 after buying an additional 11,446 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Trading Up 1.8%

NASDAQ JANX opened at $14.16 on Wednesday. The firm has a market capitalization of $851.72 million, a PE ratio of -8.43 and a beta of 2.88. The business’s 50-day moving average price is $21.05 and its two-hundred day moving average price is $23.43. Janux Therapeutics has a 12 month low of $13.26 and a 12 month high of $50.89.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. As a group, analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.